The company relies on the next generation of immune cell therapy technology to develop and research NK and CAR-NK immune cell products.
Development History
Inception
2021-2022
Beijing Qimai Yonghua Biotechnology Co., Ltd. is a biopharmaceutical innovation enterprise whose main research object is immune cells. Established in December 2021. The founders are two returnees from studying in the United States.
Expansion Period
2022-2023
The company has obtained 7 authorized invention patents and is applying for 3 patents, including 2 US patents. The patent content covers the entire process of NK cell and CAR-NK cell preparation. It solves the industry pain points and difficulties of low NK cell expansion multiplicity and low CAR-NK cell transduction rate.
Ascent Period
2024-Now
Angel round, seed round, and Series A financing have been completed. The company currently has 6 NK and CAR-NK cell products. Two have obtained IND approvals from the China (CDE) and US (FDA) State Drug Administration. Indications include: leukemia, lung cancer, ovarian cancer, breast cancer and other advanced tumor diseases, as well as various autoimmune diseases.
Online Message
Please leave your needs and suggestions, and we will contact you as soon as possible!
Quick Navigation
Contact Information
Room 401, Unit 1, Building 2, No. 25, Jinghai Fourth Road, Beijing Economic and Technological Development Area, Beijing (Beijing Pilot Free Trade Zone, High-end Industrial Zone, Yizhuang Group)
Beijing Gene MiNK Biotechnology Co., Ltd